Key points are not available for this paper at this time.
Background: Although midazolam and Dexmedetomidine regulate spinal analgesia through distinct mechanisms, no human studies assess their effects on postoperative analgesia following neuraxial administration. We Aim: looked at the clinical safety prole and length of time that effective analgesia lasted when intrathecal bupivacaine was combined with either Dexmedetomidine or Midazolam. It is a prospective study carried out in the Department of Anaesthesio Materials & Methods: logy at Malla Reddy Medical College for Women, Hyderabad. A total of 60 patients were taken and were divided into 3 groups, Control (n=20), Dexmedetomidine (n=20), and Midazolam (n=20) groups, respectively. Ethics approval was taken before the initiation of the study. The Results: Dexmedetomidine group experienced a considerably longer duration of effective analgesia (time to rst analgesic request) (286 ± 65 minutes). At the end of the rst 15 minutes following intrathecal injection, patients from the Dexmedetomidine group had a mean rank sedation score of 35.47 for Dexmedetomidine, 25.01 for Midazolam, and 30.80 for control, indicating that they were more sedated than patients from the Midazolam and control groups. There were no discernible variations in the side effects during the trial period. The duration of the two-segment sensory regression and the time to initially request analgesia were not prolonged by Midazolam. The duration of effect Conclusion: ive analgesia is greatly extended when Dexmedetomidine (5 mcg) is added to 3 mL of intrathecal hyperbaric Bupivacaine (0.5%), as compared to 1 mg of Midazolam or a placebo (0.9% normal saline), with similar occurrences of adverse effects.
Bhaskar et al. (Fri,) studied this question.